A Phase 2 interventional study of Abemaciclib and Docetaxel in Non-Small Cell Lung Cancer Stage IV, sponsored by Eli Lilly and Company. Completed at 51 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-13.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company — 6 open to participants now, 20 under way, 6 of them phase 3. Carcinoma, Non-Small-Cell Lung · Eli Lilly and Company.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 54th largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2015, is one of 73 in phase 2, and was the 113th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →6 of the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Austria and 26 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, China and 5 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Austria and 26 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, France, Japan and 2 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 41 · Phase 2 86 · Phase 3 25 · Phase 4 3
First in 2000; this study’s year is marked. 9 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 159 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 109 across the 139 interventional studies, 1,076 across the 2 observational. Of the 121 that completed or were terminated, 81 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
5 of the studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT04956640Eli Lilly and CompanyStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | 2027-04 |
| NCT06465069Eli Lilly and CompanyA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | 2027-05 |
| NCT06561685Eli Lilly and CompanyA Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the effectiveness of the study drug known as abemaciclib versus docetaxel in participants with stage IV squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 milligram (mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib
75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Docetaxel
Administered orally
Also known as: LY2835219
Administered IV
Progression Free Survival (PFS)
PFS was defined as time from the date of randomization to the date of investigator-determined disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause. Progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameters (LD) of target lesions, with reference the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant was not known to have died or have objective progression, PFS time will be censored at the day of their last radiographic tumor assessment (if available) or date of randomization if no post baseline radiographic assessment is available.
Time frame: Baseline to Objective Progression or Death from Any Cause ( Up To 6 Months)
Pharmacokinetics (PK): Clearance of Abemaciclib
Pharmacokinetics (PK): Clearance of Abemaciclib
Time frame: Cycle (C) 1 Day (D) 1: Pre-dose; C1D8: 4 and 7 hr Post-dose; C2D1: Pre-dose and 3 hr Post-dose; C3 and C4 D1:Pre-dose
PK: Volume of Distribution of Abemaciclib
PK: Volume of Distribution of Abemaciclib
Time frame: Cycle (C) 1 Day (D) 1: Pre-dose; C1D8: 4 and 7 hr Post-dose; C2D1: Pre-dose and 3 hr Post-dose; C3 and C4 D1:Pre-dose
Overall Survival (OS)
OS was defined as the time from randomization to the date of death due to any cause. For each participant who is not known to have died as the data inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.
Time frame: Baseline to Date of Death from Any Cause (Up To 28 Months)
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
Overall response was defined as the percentage of randomized participants achieving a best overall response (BoR) of complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. Participants with unevaluable or unknown response status are considered nonresponders. Complete response (CR) is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions.
Time frame: Baseline to Objective Progression (Up To 6 Months)
Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR): Disease Control Rate (DCR)
DCR is the percentage of randomized participants who achieved a complete response, partial response or stable disease using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. Complete response (CR) is defined as the disappearance of all target and non-target lesions, and no appearance of new lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions. Stable disease was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions.
Time frame: Baseline through Measured Progressive Disease or Death Due to Any Cause (Up To 6 Months)
Time to Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status of >/=2
Worsening of ECOG performance status is the duration from randomization to ECOG PFS of \>/=2. Participants without an ECOG PFS \>/=2 are censored at last adequate post baseline ECOG Performance Status or randomization date (whichever is last). The ECOG Performance Status:0 - Fully active, able to carry on all pre-disease performance without restriction,1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2 - Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours,3 - Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4 - Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5 - Dead
Time frame: Randomization to ECOG PFS of >/=2 (Up To 11.5 Months)
Change From Baseline in MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) Scores
MDASI-LC included 33 items:6 interference and 27 symptom(3 lung-cancer (LC),8 brain tumor (BT),and 3 study-specific(headache,diarrhea, and rash).Analyzed endpoints were 9 constructs:3 single-items (headache,diarrhea,and rash) and 6 composites(interference+core,LC,core+LC,BT, and core+LC worst 5 baseline).Data for all 9 constructs were collected by an 11-point numeric rating scale anchored at 0(not present or does not interfere) and 10(as bad as you can imagine or interfered completely).The measurement range was 10 (maximum score-minimum score). Between-group difference in regression-predicted change from baseline were estimated for each specified construct. MMRM models included independent variables treatment,visit, treatment\*visit,and baseline score. Group-level negative change from baseline indicated group improvement.
Time frame: Baseline through End of Study (Up To 6 Months)
Change From Baseline in EuroQol 5-Dimensional 5-Level (EQ-5D-5L) Questionnaire EQ VAS Overall Self-rated Health Score
The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Overall self-rated health was measured with a vertical 20 cm visual analog scale (VAS) anchored at 0 (worst health) and ranged through 100 (best health). Between-group differences in regression-predicted change from baseline score were estimated for VAS scores. MMRM models included independent variables treatment, visit, treatment\*visit, and baseline score. Group-level negative change from baseline indicated group improvement.
Time frame: Baseline to Measured Progressive Disease (Up To 6 Months)
Change From Baseline in EuroQol 5-Dimensional 5-Level (EQ-5D-5L) Questionnaire Index Value
There are 5 response levels on a good-to-bad continuum of 1-5 corresponding to none, slight, moderate, severe, and extreme/unable to.The EuroQol-developed crosswalk method was used to convert the EQ-5D-5L,using UK weights,health dimensions(mobility,self-care,usual activities,pain/discomfort, and anxiety/depression) into a single index value;the dimensions are not separately scored.The index is marked missing when ≥1 dimensions are missing.The index scores for the response patterns were anchored on full health to dead with negative values assigned to response patterns/health states considered worse than death.The best pattern is assigned the index value of 1.0; the worst pattern is assigned an index value of -0.594. Between-group differences in regression-predicted change from baseline score were estimated for the index .MMRM models included independent variables treatment, visit, treatment\*visit, and baseline score.Group-level negative change from baseline indicated group improvement.
Time frame: Baseline to Measured Progressive Disease (Up To 6 Months)
| Milestone | Abemaciclib | Docetaxel |
|---|---|---|
| Started | 106 | 53 |
| Received at least one dose of study drug | 106 | 52 |
| Completed | 90 | 46 |
| Not completed | 16 | 7 |
| Withdrew: Withdrawal by subject | 12 | 6 |
| Withdrew: Lost to follow-up | 4 | 1 |
PFS was defined as time from the date of randomization to the date of investigator-determined disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause. Progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameters (LD) of target lesions, with reference the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant was not known to have died or have objective progression, PFS time will be censored at the day of their last radiographic tumor assessment (if available) or date of randomization if no post baseline radiographic assessment is available.
| months | Abemaciclib | Docetaxel |
|---|---|---|
| Progression Free Survival (PFS) | 2.53 (1.68 to 2.89) | 4.21 (2.79 to 5.65) |
Pharmacokinetics (PK): Clearance of Abemaciclib
| Liters/hour (L/h) | Abemaciclib |
|---|---|
| Pharmacokinetics (PK): Clearance of Abemaciclib | 21.3 ± 36 |
PK: Volume of Distribution of Abemaciclib
| Liters (L) | Abemaciclib |
|---|---|
| PK: Volume of Distribution of Abemaciclib | 769 ± 51 |
OS was defined as the time from randomization to the date of death due to any cause. For each participant who is not known to have died as the data inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.
| Months | Abemaciclib | Docetaxel |
|---|---|---|
| Overall Survival (OS) | 7 (5.00 to 8.78) | 12.39 (7.13 to 15.98) |
Overall response was defined as the percentage of randomized participants achieving a best overall response (BoR) of complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. Participants with unevaluable or unknown response status are considered nonresponders. Complete response (CR) is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions.
| percentage participants | Abemaciclib | Docetaxel |
|---|---|---|
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) | 2.8 | 20.8 |
DCR is the percentage of randomized participants who achieved a complete response, partial response or stable disease using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. Complete response (CR) is defined as the disappearance of all target and non-target lesions, and no appearance of new lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions. Stable disease was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions.
| percentage participants | Abemaciclib | Docetaxel |
|---|---|---|
| Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR): Disease Control Rate (DCR) | 50.9 | 64.2 |
Worsening of ECOG performance status is the duration from randomization to ECOG PFS of \>/=2. Participants without an ECOG PFS \>/=2 are censored at last adequate post baseline ECOG Performance Status or randomization date (whichever is last). The ECOG Performance Status:0 - Fully active, able to carry on all pre-disease performance without restriction,1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2 - Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours,3 - Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4 - Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5 - Dead
| months | Abemaciclib | Docetaxel |
|---|---|---|
| Time to Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status of >/=2 | NA (6.58 to NA) | 10.52 (4.64 to NA) |
MDASI-LC included 33 items:6 interference and 27 symptom(3 lung-cancer (LC),8 brain tumor (BT),and 3 study-specific(headache,diarrhea, and rash).Analyzed endpoints were 9 constructs:3 single-items (headache,diarrhea,and rash) and 6 composites(interference+core,LC,core+LC,BT, and core+LC worst 5 baseline).Data for all 9 constructs were collected by an 11-point numeric rating scale anchored at 0(not present or does not interfere) and 10(as bad as you can imagine or interfered completely).The measurement range was 10 (maximum score-minimum score). Between-group difference in regression-predicted change from baseline were estimated for each specified construct. MMRM models included independent variables treatment,visit, treatment\*visit,and baseline score. Group-level negative change from baseline indicated group improvement.
| units on a scale | Abemaciclib | Docetaxel |
|---|---|---|
| Headache | 0.19 ± 0.14 | 0.01 ± 0.18 |
| Diarrhea | 1.01 ± 0.18 | 0.15 ± 0.23 |
| Mean core symptom severity | 0.53 ± 0.14 | 0.00 ± 0.18 |
| Mean interference | 0.50 ± 0.20 | 0.18 ± 0.27 |
| Mean lung cancer symptom severity | 0.20 ± 0.12 | -0.19 ± 0.15 |
| Mean core plus lung cancer symptom severity | 0.47 ± 0.13 | -0.04 ± 0.17 |
| Mean brain tumor symptom severity | 0.19 ± 0.11 | 0.13 ± 0.15 |
| Mean core plus lung worst 5 symptoms severity | -0.25 ± 0.17 | -0.94 ± 0.22 |
| Rash | 0.28 ± 0.14 | 0.18 ± 0.17 |
The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Overall self-rated health was measured with a vertical 20 cm visual analog scale (VAS) anchored at 0 (worst health) and ranged through 100 (best health). Between-group differences in regression-predicted change from baseline score were estimated for VAS scores. MMRM models included independent variables treatment, visit, treatment\*visit, and baseline score. Group-level negative change from baseline indicated group improvement.
| units on a scale | Abemaciclib | Docetaxel |
|---|---|---|
| Change From Baseline in EuroQol 5-Dimensional 5-Level (EQ-5D-5L) Questionnaire EQ VAS Overall Self-rated Health Score | -5.49 ± 1.28 | -2.36 ± 1.63 |
There are 5 response levels on a good-to-bad continuum of 1-5 corresponding to none, slight, moderate, severe, and extreme/unable to.The EuroQol-developed crosswalk method was used to convert the EQ-5D-5L,using UK weights,health dimensions(mobility,self-care,usual activities,pain/discomfort, and anxiety/depression) into a single index value;the dimensions are not separately scored.The index is marked missing when ≥1 dimensions are missing.The index scores for the response patterns were anchored on full health to dead with negative values assigned to response patterns/health states considered worse than death.The best pattern is assigned the index value of 1.0; the worst pattern is assigned an index value of -0.594. Between-group differences in regression-predicted change from baseline score were estimated for the index .MMRM models included independent variables treatment, visit, treatment\*visit, and baseline score.Group-level negative change from baseline indicated group improvement.
| units on a scale | Abemaciclib | Docetaxel |
|---|---|---|
| Change From Baseline in EuroQol 5-Dimensional 5-Level (EQ-5D-5L) Questionnaire Index Value | -0.05 ± 0.02 | -0.01 ± 0.02 |
Collected over Baseline Up To 5 Years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abemaciclib | 71/106 (67%) | 29/106 (27.4%) | 94/106 (88.7%) |
| Docetaxel | 35/52 (67.3%) | 17/52 (32.7%) | 43/52 (82.7%) |
| Event | Abemaciclib | Docetaxel |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 1/106 | 4/52 |
| Lung infectionInfections and infestations | 6/106 | 4/52 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/106 | 3/52 |
| LeukopeniaBlood and lymphatic system disorders | 0/106 | 2/52 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 3/106 | 1/52 |
| EmbolismVascular disorders | 3/106 | 0/52 |
| DiarrhoeaGastrointestinal disorders | 2/106 | 1/52 |
| NauseaGastrointestinal disorders | 1/106 | 1/52 |
| General physical health deteriorationGeneral disorders | 0/106 | 1/52 |
| PyrexiaGeneral disorders | 1/106 | 1/52 |
| Event | Abemaciclib | Docetaxel |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 18/106 | 26/52 |
| AnaemiaBlood and lymphatic system disorders | 41/106 | 12/52 |
| DiarrhoeaGastrointestinal disorders | 41/106 | 5/52 |
| NauseaGastrointestinal disorders | 33/106 | 7/52 |
| FatigueGeneral disorders | 30/106 | 7/52 |
| LeukopeniaBlood and lymphatic system disorders | 10/106 | 14/52 |
| ThrombocytopeniaBlood and lymphatic system disorders | 27/106 | 2/52 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 19/106 | 6/52 |
| Decreased appetiteMetabolism and nutrition disorders | 17/106 | 7/52 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 10/106 | 7/52 |
All randomized participants.
| Age, Continuous(years) | Abemaciclib | Docetaxel | Total |
|---|---|---|---|
| Mean | 63.1 ± 7.8 | 64.5 ± 7.1 | 63.5 ± 7.6 |
| Sex: Female, Male(Participants) | Abemaciclib | Docetaxel | Total |
|---|---|---|---|
| Female | 16 | 9 | 25 |
| Male | 90 | 44 | 134 |
| Ethnicity (NIH/OMB)(Participants) | Abemaciclib | Docetaxel | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 3 | 8 |
| Not Hispanic or Latino | 84 | 48 | 132 |
| Unknown or Not Reported | 17 | 2 | 19 |
| Race (NIH/OMB)(Participants) | Abemaciclib | Docetaxel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 10 | 3 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 96 | 50 | 146 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Abemaciclib | Docetaxel | Total |
|---|---|---|---|
| Romania | 18 | 4 | 22 |
| Hungary | 7 | 6 | 13 |
| United States | 4 | 2 | 6 |
| Ukraine | 13 | 13 | 26 |
| Russia | 11 | 2 | 13 |
| Spain | 8 | 6 | 14 |
| South Korea | 8 | 1 | 9 |
| Taiwan | 2 | 2 | 4 |
| Poland | 14 | 10 | 24 |
| Italy | 7 | 1 | 8 |
| Australia | 4 | 0 | 4 |
| France | 1 | 2 | 3 |
| Germany | 9 | 4 | 13 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)(Participants) | Abemaciclib | Docetaxel | Total |
|---|---|---|---|
| 0 | 22 | 7 | 29 |
| 1 | 84 | 46 | 130 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Aug 2015 to primary completion in Mar 2017, 19 months.
Results were first posted in Jun 2018, 1 year 2 months after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 19 months is below that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib
Carcinoma, Non-Small-Cell Lung →